KR102275824B1 - The anti-diabetes composition containing extract mixture and manufaturing method thereof - Google Patents
The anti-diabetes composition containing extract mixture and manufaturing method thereof Download PDFInfo
- Publication number
- KR102275824B1 KR102275824B1 KR1020210009573A KR20210009573A KR102275824B1 KR 102275824 B1 KR102275824 B1 KR 102275824B1 KR 1020210009573 A KR1020210009573 A KR 1020210009573A KR 20210009573 A KR20210009573 A KR 20210009573A KR 102275824 B1 KR102275824 B1 KR 102275824B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- present
- diabetes
- fruit
- preventing
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 122
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 title abstract description 15
- 229930014626 natural product Natural products 0.000 claims abstract description 29
- 235000013305 food Nutrition 0.000 claims abstract description 20
- 238000004519 manufacturing process Methods 0.000 claims abstract description 18
- 240000000249 Morus alba Species 0.000 claims abstract description 11
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 11
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 9
- 240000006079 Schisandra chinensis Species 0.000 claims abstract 2
- 235000013399 edible fruits Nutrition 0.000 claims description 29
- 238000002156 mixing Methods 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 claims description 16
- 201000006549 dyspepsia Diseases 0.000 claims description 15
- 208000024798 heartburn Diseases 0.000 claims description 15
- 241000208340 Araliaceae Species 0.000 claims description 10
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 10
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 10
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims description 10
- 235000008434 ginseng Nutrition 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 7
- 229940107131 ginseng root Drugs 0.000 claims description 7
- 238000003809 water extraction Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 4
- 244000088415 Raphanus sativus Species 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 230000001747 exhibiting effect Effects 0.000 abstract description 2
- 241001148728 Calamagrostis epigeios Species 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 28
- 210000004369 blood Anatomy 0.000 description 28
- 235000000346 sugar Nutrition 0.000 description 22
- 239000000843 powder Substances 0.000 description 14
- 230000036541 health Effects 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 208000002249 Diabetes Complications Diseases 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 10
- 235000013361 beverage Nutrition 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 229960001031 glucose Drugs 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 241000220259 Raphanus Species 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 241000736075 Schisandra Species 0.000 description 7
- 235000013355 food flavoring agent Nutrition 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 7
- 206010012655 Diabetic complications Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 235000013376 functional food Nutrition 0.000 description 6
- 235000013402 health food Nutrition 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 230000001953 sensory effect Effects 0.000 description 6
- 241001070941 Castanea Species 0.000 description 5
- 235000014036 Castanea Nutrition 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 235000007516 Chrysanthemum Nutrition 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229960001855 mannitol Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000218231 Moraceae Species 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000003975 animal breeding Methods 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 239000007970 homogeneous dispersion Substances 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- -1 pH adjusters Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000013824 Acidemia Diseases 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000723353 Chrysanthemum Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000410367 Clerodendrum thomsoniae Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000219122 Cucurbita Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 101150046735 LEPR gene Proteins 0.000 description 1
- 101150063827 LEPROT gene Proteins 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 241000218211 Maclura Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000002163 Mesapamea fractilinea Species 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 241001469893 Oxyzygonectes dovii Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000019057 Raphanus caudatus Nutrition 0.000 description 1
- 235000011380 Raphanus sativus Nutrition 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 241001521901 Tribulus lanuginosus Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229960004232 linoleic acid Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 당뇨 예방 및 개선 효과를 나타내는 복합 천연물 조성물 및 이의 제조방법에 관한 것으로, 보다 상세하게는 상심자 추출물, 오미자 추출물 및 산조씨앗 추출물을 포함하는 당뇨 예방 및 개선용 식품 조성물 및 이의 제조 방법에 관한 것이다.The present invention relates to a complex natural product composition exhibiting an effect of preventing and improving diabetes, and a method for manufacturing the same, and more particularly, to a food composition for preventing and improving diabetes comprising a heartburn extract, a Schisandra extract and a sanjo seed extract, and a method for preparing the same it's about
당뇨병은 만성 대사성 질환으로 오랜 시간이 경과함에 따라 혈관장애와 신경, 신장 및 망막 등의 기능 이상을 초래하고 이로 인해 생명까지 잃게 하는 질환이다. 당뇨병은 크게 발생하는 기전에 따라 인슐린 의존형 당뇨병(제1형 당뇨병)과 비의존형 당뇨병(제2형 당뇨병)으로 구분된다.Diabetes mellitus is a chronic metabolic disease, and over a long period of time, it causes vascular disorders and dysfunction of nerves, kidneys, and retina, and this is a disease that leads to loss of life. Diabetes is largely divided into insulin-dependent diabetes mellitus (type 1 diabetes) and non-dependent diabetes mellitus (type 2 diabetes) according to the mechanism of occurrence.
인슐린 의존형 당뇨병은 췌장 베타세포가 선택적으로 손상 또는 파괴되어 체내에서 인슐린을 생성하지 못하기 때문에 혈중 포도당을 소비하지 못하여 발병하는 것으로 알려져 있으며 심한 고혈당증과 케톤산증, 다갈, 다음, 다뇨, 체중감소 및 피로감을 나타낸다. 소아에서 흔히 발생하게 되며 이의 치료방법은 인슐린의 투여이다.Insulin-dependent diabetes mellitus is known to occur due to inability to consume blood glucose because pancreatic beta cells are selectively damaged or destroyed and the body cannot produce insulin. indicates It occurs frequently in children, and its treatment method is the administration of insulin.
인슐린 비의존형 당뇨병은 당뇨병 환자의 90% 이상을 차지하며 주로 성인에게 많이 발생한다. 그러나 뚜렷한 원인은 규명되지 않았으며 다만 유전적인 요인과 비정상적인 식생활, 스트레스, 운동, 비만, 노화 등과 같은 환경적인 요인이 복합적으로 관련되어 유발되는 것으로 추정되고 있다. 상기 인슐린 비의존형 당뇨병은 일반적으로 인슐린에 대하여 저항성을 나타내며 인슐린의 작용부전으로 인하여 과혈당 상태가 지속되는 것이 보통이다. 만성으로 경과되면 망막증, 신증, 신경장해, 동맥경화증, 감염증 및 골감소증 등의 합병증이 나타난다.Non-insulin-dependent diabetes mellitus accounts for more than 90% of diabetic patients and mainly occurs in adults. However, the exact cause has not been identified, but it is estimated that it is caused by a combination of genetic factors and environmental factors such as abnormal diet, stress, exercise, obesity, and aging. The non-insulin-dependent diabetes mellitus generally exhibits resistance to insulin, and a hyperglycemic state usually persists due to insulin insufficiency. If it progresses chronically, complications such as retinopathy, nephropathy, neuropathy, arteriosclerosis, infection and osteopenia appear.
현재 인슐린 비의존형 당뇨병의 치료법으로는 식사요법, 운동요법, 설폰요소제, 비구아니드(biguanide)계 약물, α-글루코시다아제 억제제, 인슐린 등이 이용되고 있으며 새로운 약물의 개발에 대한 많은 연구를 통해 메그리티니드계나 티아졸리디니디온계 약물, 작용시간이 다양한 인슐린 등이 개발되어 임상에 적용되고 있다. 그러나 이들 치료제들은 약효가 낮거나 간기능 장애, 저혈당, 유산혈증 등과 같은 많은 부작용을 일으키는 문제점이 있다. 따라서 이와 같은 부작용을 줄이고 대사이상 증세 등을 개선시켜 주며 장기 복용시에도 안전성이 우수한 당뇨병 치료제의 개발이 절실히 요구된다.Currently, diet therapy, exercise therapy, sulfonylurea drugs, biguanide-based drugs, α-glucosidase inhibitors, and insulin are used as treatment methods for non-insulin-dependent diabetes mellitus. Litinide-based, thiazolidinidion-based drugs, and insulin with various action times have been developed and applied to clinical practice. However, these therapeutic agents have a problem in that they have low efficacy or cause many side effects, such as liver dysfunction, hypoglycemia, and lactic acidemia. Therefore, there is an urgent need to develop a diabetes treatment agent that reduces these side effects, improves metabolic abnormalities, and has excellent safety even when taken for a long time.
한편, 상심자는 뽕나무과(Moraceae)에 속하는 뽕나무(Morus alba L) 및 동속 근연식물의 성숙한 열매로서 한방에서 오디, 상실, 오심, 흑심 등으로 지칭된다.On the other hand, heartburn is a mature fruit of Morus alba L belonging to the family Moraceae and a closely related plant.
현재 뽕나무 유래 산물 중 생리활성에 대한 연구는 주로 상백피로부터 추출되는 당단백물인 모란A (moran A)가 분리되었으며 혈당강하 물질로 보고되었다 (Hikino et al.; Planta Medica,51,pp159-256). 현대 의학적 연구 결과는 상심자의 혈당강하 작용에 대한 보고가 있으나, 상심자 추출물과 함께 작용하여 혈당 강하 작용을 강화시켜주는 추출물 조합에 대해서는 아직 연구가 미흡한 실정이다.Currently, studies on the physiological activity of mulberry-derived products have mainly isolated the glycoprotein, moran A, extracted from the epidermis and reported it as a hypoglycemic agent (Hikino et al.; Planta Medica, 51, pp159-256). Although there are reports of the blood sugar lowering effect of the broken heart as a result of modern medical research, there is still insufficient research on the extract combination that works together with the heartburn extract to enhance the blood sugar lowering action.
상심자의 혈당강하 작용에 대한 보고가 있으나, 상심자 추출물과 함께 작용하여 혈당 강하 작용을 강화시켜주는 추출물 조합에 대해서는 아직 연구가 미흡한 실정이었다.Although there have been reports on the blood sugar lowering effect of the heartbroken, studies on extract combinations that work together with the heartburn extract to enhance the blood sugar lowering action are still insufficient.
이에 상심자 추출물과 더불어, 꾸지뽕나무 열매 추출물, 오미자 열매 추출물 및 산조씨앗 추출물을 추가적으로 포함할 경우, 식 후 혈당 강하 효과가 개선됨과 동시에 기호성 또한 증가함을 확인하여 본 발명을 완성하였다.Accordingly, the present invention was completed by confirming that, in addition to the heartburn extract, Cuji mulberry fruit extract, Schisandra fruit extract and Sanjo seed extract were additionally included, the blood sugar lowering effect after a meal was improved and palatability was also increased.
본 발명의 목적은 상심자 추출물, 오미자 추출물 및 산조씨앗 추출물을 포함하는 당뇨 예방 및 개선용 식품 조성물을 제공하는 것이다.It is an object of the present invention to provide a food composition for preventing and improving diabetes, comprising a heartburn extract, a omija extract and a sanjo seed extract.
본 발명의 또 다른 목적은 상기 추출물을 포함하는 식품 조성물의 제조방법을 제공하는 것이다.Another object of the present invention is to provide a method for preparing a food composition comprising the extract.
상술한 바와 같은 목적을 달성하기 위한 본 발명은 상심자 추출물, 오미자 추출물 및 산조씨앗 추출물을 포함하는 당뇨 예방 및 개선용 식품 조성물을 제공한다.The present invention for achieving the object as described above provides a food composition for preventing and improving diabetes, comprising a heartburn extract, a omija extract and a sanjo seed extract.
상기 추출물은 열수 추출물인 것일 수 있다.The extract may be a hot water extract.
상기 추출물은 90 - 95℃ 6 - 24 시간 열수 추출한 추출물일 수 있다.The extract may be an extract extracted with hot water at 90 - 95 ° C. for 6 - 24 hours.
상기 추출물은 백자인, 꾸지뽕나무 열매, 단삼뿌리, 남가새열매 및 무씨앗을 추가로 포함하거나 모두 포함할 수 있다.The extract may further include white ginseng, mulberry fruit, ginseng root, namgasae fruit, and radish seeds or both.
상기 각 천연물의 배합 비는 상심자 : 오미자 : 산조씨앗 = 1.3 - 1.7 : 1 : 1 일 수 있다.The mixing ratio of each of the above natural products may be heartburn: omija: sanjo seed = 1.3 - 1.7: 1:1.
발명의 또다른 목적을 달성하기 위하여, (a) 상심자 1.716%, 꾸지뽕나무 열매 1.225%, 오미자 열매 1.225%, 산조씨앗 1.225%, 백자인 0.735%, 단삼뿌리 0.735%, 남가새열매 0.735% 및 무씨앗 0.735%의 중량 배합비(w/w)로 배합하는 단계; (b) 90 - 95℃에서 6 - 24시간동안 물로 열탕 추출하여 추출물을 얻는 단계; 및 (c) 여과 및 건조하는 단계;를 포함하는 당뇨 예방 및 개선용 식품 조성물의 제조 방법을 제공한다.In order to achieve another object of the invention, (a) heartworm 1.716%, mulberry fruit 1.225%, omija fruit 1.225%, sanjo seed 1.225%, white ginseng 0.735%, ginseng root 0.735%, namgasae fruit 0.735% and radish seed compounding at a weight compounding ratio (w/w) of 0.735%; (b) extracting an extract by hot water extraction at 90 - 95 °C for 6 - 24 hours; and (c) filtering and drying; provides a method for preparing a food composition for preventing and improving diabetes, including.
상기 (c) 단계 여과 후, 마이크로플루다이저(Microfluidizer) 처리를 추가적으로 수행할 수 있다.After the filtration in step (c), a microfluidizer treatment may be additionally performed.
본 발명은 상심자 추출물, 오미자 추출물 및 산조씨앗 추출물을 포함하는 당뇨 예방 및 개선용 식품 조성물 및 이의 제조 방법에 관한 것이다. 본 발명의 제조 방법으로 제조된 복합 추출물 조성물은 당뇨 예방 및 개선 효과에 뛰어나며, 오랜 기간 안정적으로 보관이 가능하다. 또한 기호성이 뛰어나 남녀노소 누구나 즐길 수 있다.The present invention relates to a food composition for preventing and improving diabetes, comprising a heartburn extract, a Schisandra extract and a sanjo seed extract, and a method for preparing the same. The complex extract composition prepared by the manufacturing method of the present invention is excellent in preventing and improving diabetes, and can be stored stably for a long time. It is also highly palatable and can be enjoyed by people of all ages and genders.
본 발명을 충분히 이해하기 위해서 본 발명의 바람직한 실시예를 참조하여 설명한다. 본 발명의 실시예는 여러 가지 형태로 변형될 수 있으며, 본 발명의 범위가 아래에서 상세히 설명하는 실시예로 한정되는 것으로 해석되어서는 안 된다. 본 실시예는 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위하여 제공되는 것이다. In order to fully understand the present invention, it will be described with reference to preferred embodiments of the present invention. Embodiments of the present invention may be modified in various forms, and the scope of the present invention should not be construed as being limited to the embodiments described in detail below. This example is provided to more completely explain the present invention to those of ordinary skill in the art.
본 명세서 전체에서, 어떤 부분이 어떤 구성요소를 "포함"한다고 할 때, 이는 특별히 반대되는 기재가 없는 한 다른 구성요소를 제외하는 것이 아니라 다른 구성 요소를 더 포함할 수 있다.Throughout this specification, when a part "includes" a certain component, it does not exclude other components unless otherwise stated, and may further include other components.
본 발명은 상심자 추출물, 오미자 추출물 및 산조씨앗 추출물을 포함하는 당뇨 예방 및 개선용 식품 조성물을 제공한다.The present invention provides a food composition for preventing and improving diabetes, comprising the heartburn extract, Schisandra extract and sanjo seed extract.
상심자(오디)는 뽕나무과(Moraceae)에 속하는 낙엽교목인 뽕나무(Morus alba L.)의 열매로, 당분, 탄닌산(tannic acid), 비타민류(vitamine), 리놀산(linolic acid) 등의 지방산 등을 함유하는 것으로 알려져 있다. 이러한 상심자는 청색에서 익으면서 자주색, 흑색으로 변할 때 채취하며, 어지러움, 이명, 구갈, 소갈, 강장, 진통약, 불면증, 요통, 변비 등에 효과가 있는 것으로 알려져 식용 및 약용으로 사용할 수 있다. Heartburn (Audrey) is the fruit of Morus alba L., a deciduous tree belonging to the family Moraceae, and contains sugars, fatty acids such as tannic acid, vitamins, and linolic acid. known to contain. These heartbroken ones are collected when they turn from blue to purple and black, and are known to be effective for dizziness, tinnitus, dry mouth, sogal, tonic, pain reliever, insomnia, back pain, and constipation, and can be used for food and medicine.
미자는 오미자과의 덩굴성 낙엽수 나무에서 열리는 과일로서, 달고 쓰고 시고 맵고 짠 다섯 가지의 맛이 난다고 하여 오미자라고 불린다. 오미자는 일반적으로 혈류 개선, 고혈압, 뇌줄중, 심혈관 질환 예방, 면역력 개선, 당뇨병 예방, 간기능 개선, 원기 회복, 호흡기 질환 개선 효능이 있는 것으로 알려져 있다. 한편, 본 발명의 일실시예에 따른 오미자는 오미자 열매, 껍질 또는 오미자청 부산물일 수 있다.Mija is a fruit that grows on a deciduous tree of the Omija family. It is called Omija because it has five flavors: sweet, bitter, sour, spicy, and salty. Omija is generally known to have the effects of improving blood flow, preventing high blood pressure, stroke, cardiovascular disease, improving immunity, preventing diabetes, improving liver function, restoring energy, and improving respiratory diseases. On the other hand, omija according to an embodiment of the present invention may be a by-product of omija fruit, skin or omijacheong.
산조씨앗이란 산조인이라고도 한다. 산조씨앗은 멧대추 씨앗의 껍데기로, 한방에서는 우울증 치료제로 상용화되고 있으며, 볶은 후 분말화하여 사용하는 것이 일반적이다.Sanjo seeds are also called sanjoin. Sanjo seeds are the husks of wild jujube seeds, which are commercialized as a treatment for depression in oriental medicine, and are generally used after roasting.
또한 본원에서 정의되는 추출물은 정제수를 포함한 물, 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합용매로부터 선택된 용매, 바람직하게는 물 또는 물 및 에탄올 혼합용매, 보다 바람직하게는 물을 포함한다. 본 발명의 추출물은 열수 추출한 추출물일 수 있다. In addition, the extract as defined herein includes a solvent selected from water including purified water, lower alcohols having 1 to 4 carbon atoms, or a mixed solvent thereof, preferably water or a mixed solvent of water and ethanol, more preferably water. The extract of the present invention may be an extract extracted with hot water.
물 또는 50 - 99% 물 및 에탄올 혼합용매를 가하여 6 내지 24시간, 바람직하게는 12시간 동안 추출한 것일 수 있다. 6시간보다 덜 추출할 경우, 유효성분이 충분히 추출되지 않을 수 있으며, 24시간보다 그 이상 추출할 경우 유효성분이 변성되거나 불필요한 성분이 과도하게 추출될 수 있다. It may be extracted for 6 to 24 hours, preferably for 12 hours by adding water or a mixed solvent of 50 - 99% water and ethanol. If the extraction is less than 6 hours, the active ingredient may not be sufficiently extracted, and if it is extracted for more than 24 hours, the active ingredient may be denatured or unnecessary ingredients may be extracted excessively.
본 발명의 추출물은 10℃ 내지 150℃, 바람직하게는 20℃ 내지 100℃, 보다 바람직하게는 90℃ 내지 95℃에서 냉침추출, 열수추출, 초음파 추출, 환류냉각 추출 등의 추출방법, 바람직하게는, 냉침추출법 또는 열수 추출법을 수행하여 추출물을 수득하는 제 1단계; 상기에서 얻은 추출물을 여과하고 여과물을 건조시키는 제 2단계의 제조공정을 통하여 본 발명의 개개 추출물을 수득할 수 있다. 가장 바람직하게는 상기 추출물은 90 - 95 ℃에서 6 - 24 시간 열수 추출한 추출물일 수 있다.The extract of the present invention is extracted by cold extraction, hot water extraction, ultrasonic extraction, reflux cooling extraction, etc. at 10°C to 150°C, preferably at 20°C to 100°C, more preferably at 90°C to 95°C, preferably , a first step of obtaining an extract by performing a cold extraction method or a hot water extraction method; Individual extracts of the present invention can be obtained through the second-step manufacturing process of filtering the extract obtained above and drying the filtrate. Most preferably, the extract may be an extract extracted with hot water at 90 - 95 °C for 6 - 24 hours.
상기 추출물은 꾸지뽕나무 열매, 단삼뿌리, 남가새열매 및 무씨앗을 추가로 포함하거나 모두 포함할 수 있다.The extract may further include or all of Cuji mulberry fruit, ginseng root, namgasae fruit and radish seeds.
꾸지뽕나무는 뽕나무과 꾸지뽕나무속에 속하는 낙엽소교목으로, 경남, 전남, 제주 등 우리나라 남쪽 지방에서 흔히 분포하며, 척박한 환경에서도 잘 자라고 병충해에 강하여 농림업 분야에서 좋은 소득작목으로 각광받고 있다. 또한, 식용이 가능한 잎과 열매에는 항암 성분이 함유되어 있으며, 민간요법으로 위암, 식도암, 간암 등에 쓰이고 있다.Cudrania is a deciduous small arboreous tree belonging to the genus Cudraniaceae, and it is commonly distributed in southern regions of Korea such as Gyeongnam, Jeollanam-do, and Jeju. In addition, edible leaves and fruits contain anticancer components, and are used as folk remedies for gastric cancer, esophageal cancer, and liver cancer.
단삼(Salviae Miltiorrhizae Radix)은 꿀풀과 다년생 식물로, 말린 뿌리를 활용하며 주로 심혈관 계통 및 어혈증 그리고 수면질환에 사용된다. Salviae Miltiorrhizae Radix is a perennial plant of the Lamiaceae family. It utilizes dried roots and is mainly used for cardiovascular system, sepsis, and sleep disorders.
남가새(Tribulus terrestris)는 질려자 등의 이명으로도 불린다. 줄기는 밑에서 가지를 치며 갈라져서 옆으로 자라고, 길이는 1m 정도에 달한다. 잎은 길이 1~6㎝로서 짧은 자루가 있고, 작은 피침상 삼각형의 탁엽이 있다. 작은 잎은 긴 타원형으로 양쪽이 같지 않으며, 잎 뒤에 백색 눈털이 있다. 원산지는 한국, 인도, 대만 등지로 알려져 있다. 고혈압, 안과질환, 간 보호에 효능이 있다고 알려져 있다.Namgasae ( Tribulus terrestris ) is also called by other names such as tiredness. Stems branch from the bottom, split and grow sideways, reaching about 1m in length. The leaves are 1-6 cm long, have short stalks, and have small lanceolate triangular stipules. The small leaves are long oval and both sides are not the same, and there are white eye hairs behind the leaves. The place of origin is known as Korea, India, and Taiwan. It is known to be effective for high blood pressure, ophthalmic diseases, and liver protection.
무씨앗이란 나복자라고도 불린다. 나복자는 십자화과에 속한 식물로 무(Raphanus sativus L.)의 여문 종자이다. 말린 종자는 타원형이거나 둥근 난형과 비슷한데 조금 편평하며 길이는 약 3mm, 너비는 2.5mm이다. 표면은 적갈색이며 한쪽에 세로 홈이 몇 개 있고 한쪽 끝에 밑씨가 있다. 밑씨는 갈색이고 둥근 점 모양으로 도드라져 있다. 확대경으로 관찰하면 씨 전체에 그물무늬가 촘촘히 있다. 질은 단단하고 쪼개면 황백색 혹은 누런 알맹이가 보이고 알맹이에 정유가 있다. 여름과 가을에 종자가 여물면 포기를 베어 햇볕에 말렸다가 손으로 비벼 씨를 빼내어, 잡물을 제거한 후 햇볕에 말린 후 한약재로 사용한다Radish seeds are also called lepers. Leprosy is a plant belonging to the cruciferous family and is the ripening seed of radish (Raphanus sativus L.). Dried seeds are oval or round ovate, slightly flattened, about 3mm long and 2.5mm wide. The surface is reddish-brown, with several longitudinal grooves on one side and an ovule at one end. The ovule is brown and has a round dot shape. When observed with a magnifying glass, the entire seed has fine net patterns. The quality is hard and when it is cracked, yellowish-white or yellowish grains are visible and the grains contain essential oil. In summer and autumn, when the seeds are ripe, cut the vines, dry them in the sun, rub them with your hands to remove the seeds, remove foreign substances, and dry them in the sun to use as herbal medicine.
상기 추출물은 추가적으로 황금, 사삼, 건율, 여정자, 국화, 백자인 및 청호로 구성되는 군에서 선택되는 어느 하나 이상을 포함할 수 있다.The extract may additionally include any one or more selected from the group consisting of gold, ginseng, geunyul, jainja, chrysanthemum, white ginseng, and cheongho.
실시예 5 내지 7에 따라 황금, 사삼, 건율, 여정자, 국화, 백자인 및 청호를 추가적으로 포함하였을 때, 더 나은 혈당 강하 효과(표 4 및 5), 저장능(표 6) 및 관능성(표 7)을 보인다는 것을 확인하였다.According to Examples 5 to 7, when gold, ginseng, dryness, traveler, chrysanthemum, white ginseng and cheongho were additionally included, better blood sugar lowering effect (Tables 4 and 5), storage capacity (Table 6) and sensuality (Table 7) ) was confirmed to be visible.
상기 각 천연물의 배합 비는 상심자 : 오미자 : 산조씨앗 = 1.3 - 1.7 : 1 : 1 : 1 일 수 있다. The mixing ratio of each of the above natural products may be heartburn: omija: sanjo seed = 1.3 - 1.7: 1: 1: 1: 1.
본 발명자는 실시예 1의 배합 비로 제조될 때, 가장 보존성이 높으면서 최적의 혈당 강하 효과 및 관능성을 가진다는 것을 확인하였다.The present inventors have confirmed that when prepared in the blending ratio of Example 1, it has the highest preservability and optimal blood sugar lowering effect and sensory properties.
본 발명자는 각 추출물들의 여러가지 배합과 배합 비율에 대한 실험을 진행하였다(실시예 1 내지 10 참조). 남가새열매, 무씨앗, 꾸지뽕열매 및 단삼뿌리를 추가할 경우 더 나은 혈당 강하 효과가 나타남을 확인하였다. 또한, 황금, 사삼, 건율, 여정자, 국화, 백자인 및 청호를 추가할 경우 보존성 및 관능성이 향상되는 것을 확인하였다.The present inventors conducted experiments on various formulations and mixing ratios of each extract (see Examples 1 to 10). It was confirmed that a better blood sugar lowering effect was obtained when namgasae fruit, radish seeds, cucurbita fruit and dandelion root were added. In addition, it was confirmed that the preservation and sensuality were improved when gold, sasan, geonyul, jainja, chrysanthemum, white ginseng and cheongho were added.
또한 본원에서 정의되는 당뇨는 1형 당뇨병 및 2형 당뇨병, 바람직하게는 2형 당뇨병을 포함한다.Diabetes as defined herein also includes type 1 diabetes and type 2 diabetes, preferably type 2 diabetes.
상기와 같은 방법으로 얻은 본 발명의 추출물을 db/db생쥐모델을 이용한 혈당 측정실험을 수행한 결과, 탁월한 혈당강하 효과를 확인할 수 있었다.As a result of performing a blood glucose measurement experiment using the db/db mouse model of the extract of the present invention obtained by the above method, an excellent blood glucose lowering effect was confirmed.
또한, 본 발명의 복합 천연물 추출물은 오랫동안 식용되거나 생약으로 사용되어 오던 약재로서 이로부터 추출된 본 발명의 추출물들 역시 독성 및 부작용 등의 문제가 없다.In addition, the complex natural product extract of the present invention is a drug that has been edible or used as a herbal medicine for a long time, and the extracts of the present invention extracted therefrom also do not have problems such as toxicity and side effects.
본 발명은 혈당강하 효과를 갖는 본 발명의 복합 천연물 추출물을 유효성분으로 함유하는 당뇨 예방 및 개선용 건강기능식품을 제공한다.The present invention provides a health functional food for preventing and improving diabetes containing the complex natural product extract of the present invention having a hypoglycemic effect as an active ingredient.
본원에서 정의되는 "건강기능식품"은 건강기능식품에 관한 법률 제6727호에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 의미하며, "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다."Health functional food" as defined herein means a food manufactured and processed using raw materials or ingredients useful for the human body according to Act No. 6727 of the Health Functional Food Act. It refers to ingestion for the purpose of obtaining useful effects for health purposes such as regulating nutrients with respect to structure and function or physiological effects.
본 발명의 당뇨병 및 당뇨합병증 예방을 위한 건강기능식품은, 조성물 총 중량에 대하여 상기 추출물을 0.01 내지 95 %, 바람직하게는 1 내지 80 % 중량 백분율로 포함한다.The health functional food for preventing diabetes and diabetic complications of the present invention contains the extract in an amount of 0.01 to 95%, preferably 1 to 80% by weight based on the total weight of the composition.
또한, 당뇨병 및 당뇨합병증 예방을 위한 목적으로 정제, 캅셀, 분말, 과립, 액상, 환 등의 형태인 건강기능식품으로 제조 및 가공이 가능하다.In addition, it is possible to manufacture and process health functional foods in the form of tablets, capsules, powders, granules, liquids, pills, etc. for the purpose of preventing diabetes and diabetic complications.
본 발명은 혈당 개선, 지질대사의 개선 및 당뇨병 및 당뇨합병증 합병증의 예방 및 치료의 효과를 나타내는 상기 추출물을 포함하는 건강보조식품을 제공한다. 상기 추출물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강 기능성 식품류 등이 있다.The present invention provides a dietary supplement comprising the extract showing the effect of improving blood sugar, improving lipid metabolism, and preventing and treating diabetes and diabetic complications. Foods to which the extract can be added include, for example, various foods, beverages, gum, tea, vitamin complexes, health functional foods, and the like.
또한, 혈당 개선, 지질대사 개선 및 당뇨병 및 당뇨합병증 합병증의 예방 및 치료 효과를 목적으로 식품 또는 음료에 첨가될 수 있다. 이 때, 식품 또는 음료 중의 상기 추출물의 양은 전체 식품 중량의 0.01 내지 15 중량%로 가할 수 있으며, 건강 음료 조성물은 100 ㎖를 기준으로 0.02 내지 5g, 바람직하게는 0.3 내지 1g의 비율로 가할 수 있다.In addition, it may be added to food or beverage for the purpose of improving blood sugar, improving lipid metabolism, and preventing and treating complications of diabetes and diabetic complications. At this time, the amount of the extract in the food or beverage may be added in 0.01 to 15% by weight of the total food weight, and the health beverage composition may be added in a ratio of 0.02 to 5g, preferably 0.3 to 1g based on 100 ml. .
본 발명의 건강 기능성 음료 조성물은 지시된 비율로 필수 성분으로서 상기 추출물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 1 내지 20g, 바람직하게는 약 5 내지 12g이다.The health functional beverage composition of the present invention is not particularly limited in other ingredients except for containing the extract as an essential ingredient in the indicated ratio, and may contain various flavoring agents or natural carbohydrates as additional ingredients like a conventional beverage. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. As flavoring agents other than those described above, natural flavoring agents (taumatine, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 추출물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 시료는 천연 과일 주스 및 과일 주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 시료 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the extract of the present invention contains various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages, and the like. In addition, the sample of the present invention may contain natural fruit juice and pulp for the production of fruit juice beverages and vegetable beverages. These components may be used independently or in combination. The proportion of these additives is not so important, but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the sample of the present invention.
본 발명의 복합 천연물 추출물은 당뇨병 및 당뇨합병증 예방 및 치료용도의 약학 조성물로도 사용될 수 있다. The complex natural extract of the present invention can also be used as a pharmaceutical composition for preventing and treating diabetes and diabetic complications.
본 발명의 복합 천연물 추출물을 함유하는 당뇨병 및 당뇨합병증 예방 및 치료용 약학조성물은 조성물 총 중량에 대하여 상기 추출물을 0.1 내지 50% 중량백분율로 포함한다.The pharmaceutical composition for preventing and treating diabetes and diabetic complications containing the complex natural extract of the present invention contains the extract in an amount of 0.1 to 50% by weight based on the total weight of the composition.
본 발명의 추출물을 포함하는 약학조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.The pharmaceutical composition comprising the extract of the present invention may further include suitable carriers, excipients and diluents commonly used in the preparation of pharmaceutical compositions.
본 발명의 추출물의 약학적 투여 형태는 이들의 약학적 허용가능한 염의 형태로도 사용될 수 있고, 또한 단독으로 또는 타 약학적 활성 화합물과 결합뿐만 아니라 적당한 집합으로 사용될 수 있다.The pharmaceutical dosage form of the extract of the present invention may be used in the form of a pharmaceutically acceptable salt thereof, and may be used alone or in combination with other pharmaceutically active compounds as well as in an appropriate group.
본 발명에 따른 추출물을 포함하는 약학조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 추출물을 포함하는 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트 (Calcium carbonate), 수크로스 (Sucrose) 또는 락토오스 (Lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜 (Propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔 (Witepsol), 마크로골, 트윈 (Tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.The pharmaceutical composition comprising the extract according to the present invention is in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., external preparations, suppositories, and sterile injection solutions, respectively, according to conventional methods. It can be formulated and used. Carriers, excipients and diluents that may be included in the composition comprising the extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate , cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, it is prepared using diluents or excipients, such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient in the extract, for example, starch, calcium carbonate, sucrose ) or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid formulations for oral use include suspensions, solutions, emulsions, syrups, etc. In addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used. As the base of the suppository, Witepsol, macrogol, Tween 61, cacao butter, laurin fat, glycerogelatin, etc. may be used.
본 발명의 추출물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나, 바람직한 효과를 위해서, 본 발명의 추출물은 1일 0.0001 내지 100 mg/kg으로, 바람직하게는 0.001 내지 100 mg/kg으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The preferred dosage of the extract of the present invention varies depending on the condition and weight of the patient, the degree of disease, the drug form, the route and duration of administration, but may be appropriately selected by those skilled in the art. However, for a desirable effect, the extract of the present invention is preferably administered at 0.0001 to 100 mg/kg per day, preferably at 0.001 to 100 mg/kg. Administration may be administered once a day, or may be administered in several divided doses. The above dosage does not limit the scope of the present invention in any way.
본 발명의 추출물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관내 (Intracerebroventricular) 주사에 의해 투여될 수 있다. 가장 바람직하게는 경구 투여 방식일 수 있다.The extract of the present invention may be administered to mammals such as rats, mice, livestock, and humans by various routes. Any mode of administration can be envisaged, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection. Most preferably, it may be an oral administration method.
본원 발명의 상기 부형제, 결합제, 붕해제, 활택제, 교미제, 착향료 등에 대한 용어 정의는 당업계에 공지된 문헌에 기재된 것으로 그 기능 등이 동일 내지 유사한 것들을 포함한다 (대한약전 해설편, 문성사, 한국약학대학협의회, 제 5 개정판, p33-48, 1989 ).The term definitions for the excipients, binders, disintegrants, lubricants, flavoring agents, and the like of the present invention are those described in documents known in the art and include those having the same or similar functions (Explanation of the Korean Pharmacopoeia, Moonseongsa) , Korea Association of Pharmacy Colleges, 5th edition, p33-48, 1989).
발명의 또다른 목적을 달성하기 위하여, (a) 상심자 1.716, 꾸지뽕나무 열매 1.225, 오미자 열매 1.225, 산조씨앗 1.225, 백자인 0.735, 단삼뿌리 0.735, 남가새열매 0.735 및 무씨앗 0.735의 중량 배합비로 배합하는 단계; (b) 90 - 95℃에서 6 - 24시간동안 물로 열탕 추출하여 추출물을 얻는 단계; 및 (c) 여과 및 건조하는 단계;를 포함하는 당뇨 예방 및 개선용 식품 조성물의 제조 방법을 제공한다.In order to achieve another object of the present invention, (a) 1.716 chestnut berry, 1.225 mulberry fruit, 1.225 omija fruit, 1.225 sanjo seed 1.225, white ginseng 0.735, ginseng root 0.735, namgasae fruit 0.735 and radish seed 0.735 in a weight ratio step; (b) extracting an extract by hot water extraction at 90 - 95 °C for 6 - 24 hours; and (c) filtering and drying; provides a method for preparing a food composition for preventing and improving diabetes, including.
상기 (c) 단계 여과 후, 마이크로플루다이저(Microfluidizer) 처리를 추가적으로 수행할 수 있다. 실시예 11은 마이크로플루다이저 처리를 진행한 추출물인데, 실시예 11이 기존 실시예 1 대비 더 나은 혈당 강하 효과를 나타내었다. 추출물 내 유효성분들간 응집된 입자를 분쇄하여 균질 분산액으로 제조하므로, 보다 나을 효과를 나타낸 것으로 파악된다.After the filtration in step (c), a microfluidizer treatment may be additionally performed. Example 11 is an extract treated with a microfluidizer, and Example 11 exhibited a better blood sugar lowering effect than that of Example 1. Since the aggregated particles between the active ingredients in the extract are pulverized to prepare a homogeneous dispersion, it is understood that a better effect is exhibited.
이하 본 발명의 실시예에 따른 제조 방법에 대하여 자세히 설명한다.Hereinafter, a manufacturing method according to an embodiment of the present invention will be described in detail.
<실시예 1><Example 1>
경동시장(서울)에서 구입한 상심자 1.716%, 오미자 열매 1.225%, 산조씨앗 1.225%의 중량 배합비(w/w)로 배합하여 95℃에서 12시간동안 물로 열탕 추출하여 추출물을 얻고 이를 여과 및 건조시켜 천연물 복합 추출물을 수득하여 하기 실험에 사용하였다.The extract was obtained by mixing 1.716% chestnuts purchased at Gyeongdong Market (Seoul), 1.225% omija fruit, and 1.225% sanjo seeds in a weight mixing ratio (w/w) and extracting it with boiling water at 95°C for 12 hours to obtain an extract, which was filtered and dried. to obtain a natural product complex extract and used in the following experiment.
<실시예 2 - 4><Examples 2 - 4>
* 표 안에 기재된 숫자는 중량 배합비(w/w)를 나타냄* Numbers in the table indicate the weight mixing ratio (w/w)
상기 표 1에 기재된 천연물을 추가적으로 사용한 것을 제외하고는 실시예 1과 동일하게 행하여 천연물 복합 추출물을 수득하였다.A natural product complex extract was obtained in the same manner as in Example 1, except that the natural products described in Table 1 were additionally used.
<실시예 5 - 7><Examples 5 - 7>
* 표 안에 기재된 숫자는 중량 배합비(w/w)를 나타냄* Numbers in the table indicate the weight mixing ratio (w/w)
상기 표 2에 기재된 것 천연물을 추가적으로 사용한 것을 제외하고는 실시예 1과 동일하게 행하여 천연물 복합 추출물을 수득하였다.A natural product complex extract was obtained in the same manner as in Example 1, except that the natural products described in Table 2 were additionally used.
<실시예 8 - 10><Examples 8 - 10>
* 표 안에 기재된 숫자는 중량 배합비(w/w)를 나타냄* Numbers in the table indicate the weight mixing ratio (w/w)
상기 표 3에 기재된 상심자, 오미자 및 산조씨앗의 중량 배합비로 천연물을 혼합 사용한 것을 제외하고는 실시예 1과 동일한 방식으로 천연물 복합 추출물을 수득하였다.A natural product complex extract was obtained in the same manner as in Example 1, except that natural products were mixed and used in the weight mixing ratio of chestnut seed, omija and sanjo seeds described in Table 3 above.
<실시예 11><Example 11>
경동시장(서울)에서 구입한 상심자 1.716%, 오미자 열매 1.225%, 산조씨앗 1.225%의 중량 배합비(w/w)로 배합하여 95℃에서 12시간동안 물로 열탕 추출하여 추출물을 얻고, 이를 여과시켰다. 여과 후 마이크로플루다이저(ZEUS, M-110P)를 사용하여 응집된 입자를 분쇄하여 균질분산액을 제조하는 단계를 추가적으로 수행하였다. 그 후, 건조시켜 천연물 복합 추출물을 수득하여 하기 실험에 사용하였다.The extract was obtained by mixing 1.716% chestnuts purchased at Gyeongdong Market (Seoul), 1.225% omija fruit, and 1.225% sanjo seeds in a weight mixing ratio (w/w), followed by hot water extraction at 95°C for 12 hours to obtain an extract, which was filtered. . After filtration, a step of preparing a homogeneous dispersion by pulverizing the agglomerated particles using a microfluidizer (ZEUS, M-110P) was additionally performed. Thereafter, it was dried to obtain a natural product complex extract and used in the following experiment.
<비교예 1><Comparative Example 1>
상기 <실시예 1>의 제조 방법에서 별도 천연 추출물을 첨가하지 않고 비교예1을 제조하였다.Comparative Example 1 was prepared without adding a separate natural extract in the preparation method of <Example 1>.
<실험예1><Experimental Example 1>
정상 쥐에 미치는 혈당강하효과 확인Confirmation of hypoglycemic effect on normal rats
정상 마우스 3주령(몸무게 25 ± 2g)을 분양받아 1주간 동물 사육실에서 적응을 시킨 후 각 실험군을 2마리씩 배정하였다. 1조에 2마리씩 12개조(실시에 1-11 및 비교예 1)로 나누어 넣었다. 4주령에서 혈당측정을 1일 간격으로 총 3일간 수행하였다.Normal mice 3 weeks old (weight 25 ± 2 g) were received and acclimatized in an animal breeding room for 1 week, and then 2 mice were assigned to each experimental group. Two animals per group were divided into 12 groups (Example 1-11 and Comparative Example 1). At 4 weeks of age, blood glucose measurements were performed at 1 day intervals for a total of 3 days.
그리고 천연물 복합 추출물을 매일 오전 10시와 오후 16시에 마우스존데를 이용하여 0.2ml씩 경구 투여하였다. 혈당측정은 아침 식이 10분 후, 추출물 복용 후 10분 후에 총 1일 2회 측정하였다. 혈당 측정은 마우스 꼬리 미정맥에서 휴대용 혈당계 (OneTOUCH@Ultra, Johnson & Johnson, USA)로 측정하였다.And the natural product complex extract was orally administered at 10 am and 16 pm every day by using a mouse sonde. Blood glucose was measured twice a day, 10 minutes after breakfast and 10 minutes after taking the extract. Blood glucose was measured in the tail vein of the mouse with a portable glucometer (OneTOUCH@Ultra, Johnson & Johnson, USA).
측정된 결과는 표 4에 나타내었다.The measured results are shown in Table 4.
(mg/dL)(mg/dL)
(mg/dL)(mg/dL)
(%)(%)
(mg/dL)(mg/dL)
(mg/dL)(mg/dL)
(%)(%)
* 두 마우스의 평균값 기재상기 표 4에 기재된 결과로 부터 알 수 있는 바와 같이, 본 발명의 건강보조식품은 정상 쥐에서 혈당강하효과를 나타낸다.* Describe the average value of two mice As can be seen from the results shown in Table 4, the dietary supplement of the present invention exhibits a hypoglycemic effect in normal mice.
<실험예 2> <Experimental Example 2>
당뇨 동물 모델을 이용한 항당뇨 효과 확인Confirmation of anti-diabetic effect using diabetic animal model
본 발명의 복합 천연물 추출물을 기존의 약물인 메트포르민과의 비교 검증을 위하여 제2형 당뇨의 대표적인 동물모델에서 항당뇨 및 항고지혈증의 예방 또는 치료효과를 검증하고자 수행되었다.It was performed to verify the preventive or therapeutic effect of antidiabetic and antihyperlipidemia in a representative animal model of type 2 diabetes for comparative verification of the complex natural extract of the present invention with the existing drug metformin.
BKS.Cg-m+/+Leprdb/Jhomozygousdiabetic(db/db) 생쥐(20g, 중앙실험동물) 3주령(몸무게 20 ± 2g)을 분양받아 1주간 동물 사육실에서 적응을 시킨 후 각 실험군을 2마리씩 배정하였다. 1조에 2마리씩 13개조(실시에 1-11 및 비교예 1-2)로 나누어 넣었다. 비교예 2는 양성 대조군으로 메트포르민(150mg/kg/day)을 투약하였다. BKS.Cg-m +/+ Lepr db/J homozygousdiabetic ( db/db) mice (20g, central experimental animal) 3 weeks old (weight 20 ± 2g) were received and acclimatized in the animal breeding room for 1 week. were assigned to each. Two animals per group were divided into 13 groups (Example 1-11 and Comparative Example 1-2). In Comparative Example 2, metformin (150 mg/kg/day) was administered as a positive control.
4주령에서 혈당측정을 1일 간격으로 총 3일간 수행하였다.At 4 weeks of age, blood glucose measurements were performed at 1 day intervals for a total of 3 days.
그리고 천연물 복합 추출물을 매일 오전 10시와 오후 16시에 마우스존데를 이용하여 0.2ml씩 경구 투여하였다. 혈당측정은 아침 식이 10분 후, 추출물 복용 후 10분 후에 총 1일 2회 측정하였다. 혈당 측정은 마우스 꼬리 미정맥에서 휴대용 혈당계(OneTOUCH@Ultra, Johnson & Johnson, USA)로 측정하였다.And the natural product complex extract was orally administered at 10 am and 16 pm every day by using a mouse sonde. Blood glucose was measured twice a day, 10 minutes after breakfast and 10 minutes after taking the extract. Blood glucose was measured in the tail vein of the mouse with a portable glucometer (OneTOUCH@Ultra, Johnson & Johnson, USA).
측정된 결과는 표 5에 나타내었다.The measured results are shown in Table 5.
(mg/dL)(mg/dL)
(mg/dL)(mg/dL)
(%)(%)
(mg/dL)(mg/dL)
(mg/dL)(mg/dL)
(%)(%)
* 두 마우스의 평균값 기재* Write the average value of two mice
<실험예 3> <Experimental Example 3>
저장능 평가storage capacity evaluation
위 실시예 및 비교예로 제조한 복합 천연물 추출물을 저장 온도 30℃에 각각 10일간 보관한 후, 부유물 발생 정도와 부패취를 확인하였다.After storing the complex natural product extracts prepared in the above Examples and Comparative Examples at a storage temperature of 30° C. for 10 days, the degree of occurrence of floating matter and the odor of decay were confirmed.
부유물 발생 정도는 흡광광도계로 측정하여, 기존 대비 불용성 부유물이 발생했는지 확인하였다. 기존 값 대비 흡광도 값이 크게 오른 것은 +++로 표시하고, 처음과 거의 변화가 없는 것은 -로 표시하였다.The degree of occurrence of suspended solids was measured with an absorptiometer, and it was confirmed whether insoluble suspended solids were generated compared to the existing ones. A significant increase in the absorbance value compared to the previous value is indicated by +++, and a case with little change from the initial value is indicated by -.
부패취는 냄새측정기(OMX-SRM)를 이용하여 측정하였다. 수치가 클수록 부패취가 심한 것으로 판단할 수 있다.The odor of putrefaction was measured using an odor meter (OMX-SRM). It can be judged that the higher the number, the more severe the smell of decay.
저장 안정성 평가 결과는 아래 표 6에 나타난 바와 같다.The storage stability evaluation results are shown in Table 6 below.
상기 표 6를 살펴보면, 실시예로 복합 천연물 추출물에서 부유물 발생이 적게 이뤄지거나 거의 발생하지 않았다. 또 부패취 역시 상대적으로 매우 적게 확인되었다. 천연 미생물 억제제인 천연 추출물의 첨가가 부유물 발생을 억제하고 부패취를 방지해 주는 것으로 판단된다.Looking at Table 6, the generation of suspended matter was made less or hardly occurred in the complex natural product extract as an example. In addition, the odor of decay was also confirmed to be relatively low. It is judged that the addition of a natural extract, a natural microorganism inhibitor, suppresses the generation of floating matter and prevents the rotting odor.
<실험예 4> <Experimental Example 4>
관능 검사sensory test
상기 실시예 1-11에서 제조한 복합 천연물 추출물에 대한 관능검사를 실시하였다. 실시예 1-11의 추출물은 음료 형태로 가공하여, 제품의 맛, 냄새, 전체적기호도 (5= 아주 좋다, 3=좋지도 싫지도 않다, 1= 아주 나쁘다)를 5명의 panel 요원을 선정하여, 5점 척도법으로 검사하였다. A sensory test was performed on the complex natural product extract prepared in Examples 1-11. The extracts of Examples 1-11 were processed into beverages, and the taste, smell, and overall preference of the product (5 = very good, 3 = neither good nor bad, 1 = very bad) were selected by 5 panel personnel, It was tested on a 5-point scale.
하기 관능검사 항목에 대한 각각의 수치는 관능검사요원들의 점수의 총합을 관능검사요원수로 나눈 후 소수 첫째자리에서 반올림한 값으로 관능검사 항목에서 수치가 높을수록 관능성이 우수함을 의미한다Each numerical value for the following sensory test items is a value rounded to the first decimal place after dividing the sum of the scores of sensory test agents by the number of sensory test agents.
상기 표 7를 살펴보면, 실시예 11로 제조된 복합 천연물 추출물이 가장 높은 관능성을 가지는 것으로 나타났다. Looking at Table 7, it was found that the complex natural product extract prepared in Example 11 had the highest functionality.
<제제예 1><Formulation Example 1>
산제의 제조Preparation of powders
본 발명의 천연물 복합 추출물 20 mg20 mg of the natural product complex extract of the present invention
유당 100 mgLactose 100 mg
탈크 10 mgtalc 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.A powder is prepared by mixing the above ingredients and filling an airtight bag.
<제제예 2><Formulation Example 2>
정제의 제조manufacture of tablets
본 발명의 천연물 복합 추출물 10 mg10 mg of natural product complex extract of the present invention
옥수수전분 100 mg100 mg cornstarch
유당 100 mgLactose 100 mg
스테아린산 마그네슘 2 mg2 mg magnesium stearate
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.After mixing the above ingredients, tablets are prepared by tableting according to a conventional manufacturing method of tablets.
<제제예 3><Formulation Example 3>
캅셀제의 제조Preparation of capsules
본 발명의 천연물 복합 추출물 10 mg10 mg of natural product complex extract of the present invention
결정성 셀룰로오스 3 mg3 mg of crystalline cellulose
락토오스 14.8 mgLactose 14.8 mg
마그네슘 스테아레이트 0.2 mg0.2 mg magnesium stearate
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.According to a conventional capsule preparation method, the above ingredients are mixed and filled in a gelatin capsule to prepare a capsule.
<제제예 4><Formulation Example 4>
주사제의 제조manufacture of injections
본 발명의 천연물 복합 추출물 10 mg10 mg of natural product complex extract of the present invention
만니톨 180 mgmannitol 180 mg
주사용 멸균 증류수 2974 mg2974 mg of sterile distilled water for injection
Na2HPO412H2O 26 mgNa 2 HPO 4 12H 2 O 26 mg
통상의 주사제의 제조방법에 따라 1 앰플당 (2 ㎖) 상기의 성분 함량으로 제조한다.According to a conventional method for preparing injections, the content of the above ingredients per 1 ampoule (2 ml) is prepared.
<제제예 5><Formulation Example 5>
액제의 제조Preparation of liquids
본 발명의 천연물 복합 추출물 20 mg20 mg of the natural product complex extract of the present invention
이성화당 10 g10 g isomerized sugar
만니톨 5 g5 g of mannitol
정제수 적량Purified water appropriate amount
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 정제수를 가하여 전체 100 ㎖로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조한다.According to a conventional liquid preparation method, each component is added to purified water to dissolve, an appropriate amount of lemon flavor is added, the above components are mixed, purified water is added, the whole is adjusted to 100 ml by adding purified water, and then filled in a brown bottle. Sterilize to prepare a solution.
<제제예 6> <Formulation Example 6>
건강 식품의 제조manufacturing of health food
본 발명의 천연물 복합 추출물 1000 mg1000 mg of the natural product complex extract of the present invention
비타민 혼합물 적량appropriate amount of vitamin mixture
비타민 A 아세테이트 70 ㎍70 μg vitamin A acetate
비타민 E 1.0 ㎎Vitamin E 1.0 mg
비타민 B1 0.13 ㎎Vitamin B1 0.13 mg
비타민 B2 0.15 ㎎Vitamin B2 0.15 mg
비타민 B6 0.5 ㎎Vitamin B6 0.5 mg
비타민 B12 0.2 ㎍0.2 μg of vitamin B12
비타민 C 10 ㎎Vitamin C 10 mg
비오틴 10 ㎍Biotin 10 μg
니코틴산아미드 1.7 ㎎Nicotinamide 1.7 mg
엽산 50 ㎍50 μg folic acid
판토텐산 칼슘 0.5 ㎎Calcium pantothenate 0.5 mg
무기질 혼합물 적량Mineral mixture appropriate amount
황산제1철 1.75 ㎎Ferrous sulfate 1.75 mg
산화아연 0.82 ㎎Zinc oxide 0.82 mg
탄산마그네슘 25.3 ㎎Magnesium carbonate 25.3 mg
제1인산칼륨 15 ㎎Potassium monophosphate 15 mg
제2인산칼슘 55 ㎎Dibasic calcium phosphate 55 mg
구연산칼륨 90 ㎎Potassium citrate 90 mg
탄산칼슘 100 ㎎Calcium carbonate 100 mg
염화마그네슘 24.8 ㎎Magnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.The composition ratio of the vitamin and mineral mixture is a composition that is relatively suitable for health food in a preferred embodiment, but the mixing ratio may be arbitrarily modified, and the ingredients are mixed according to a conventional health food manufacturing method. , to prepare granules, and can be used for preparing health food compositions according to a conventional method.
<제제예 7><Formulation Example 7>
건강 음료의 제조manufacture of health drinks
본 발명의 천연물 복합 추출물 1000 mg1000 mg of the natural product complex extract of the present invention
구연산 1000 ㎎citric acid 1000 mg
올리고당 100 g100 g of oligosaccharides
매실농축액 2 g2 g of plum concentrate
타우린 1 g1 g taurine
정제수를 가하여 전체 900 ㎖Total 900 ml by adding purified water
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2ℓ 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다.After mixing the above ingredients according to a conventional health drink manufacturing method, stirring and heating at 85° C. for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2L container, sealed and sterilized, and then refrigerated. used in the manufacture of health beverage compositions.
<제제예 8><Formulation Example 8>
혼합추출분말 건강식품Mixed extract powder health food
아래의 배합 비율로 혼합된 혼합 추출분말 건강식품을 제조한다.Prepare mixed extract powder health food mixed in the following mixing ratio.
덱스트린 91.179%Dextrin 91.179%
본 발명의 천연물 복합 추출물 8.821% (상심자 추출 분말 1.716%, 꾸지뽕나무열매 추출 분말 1.225%, 오미자열매 추출 분말 1.225%, 산조씨앗 추출 분말 1.225%, 단삼뿌리 추출 분말 0.735%, 백자인 0.735%, 남가새열매 추출 분말 0.735%, 무씨앗 추출 분말 0.735%)Natural product complex extract of the present invention 8.821% (1.716% of chestnut extract powder, 1.225% of mulberry extract powder, 1.225% of Schisandra fruit extract powder, 1.225% of sanjo seed extract powder, 0.735% of ginseng root extract powder, 0.735% of white ginseng, Fruit Extract Powder 0.735%, Radish Seed Extract Powder 0.735%)
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the composition ratio is prepared by mixing ingredients suitable for relatively favorite beverages in a preferred embodiment, the mixing ratio may be arbitrarily modified according to regional and national preferences such as demand class, demanding country, and use.
이상으로 본 발명의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현 예일뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.As described above in detail a specific part of the present invention, for those of ordinary skill in the art, this specific description is only a preferred embodiment, and it is clear that the scope of the present invention is not limited thereto. Accordingly, the substantial scope of the present invention will be defined by the appended claims and their equivalents.
Claims (4)
A food composition for preventing and improving diabetes, characterized in that it contains a heartburn extract, a Schisandra extract and a sanjo seed extract, and the weight mixing ratio of each natural product is heartburn: omija: sanjo seed = 1.3 - 1.7: 1:1.
[Claim 2] The food composition for preventing and improving diabetes according to claim 1, wherein the food composition further comprises a ginseng root extract, namgasae fruit extract, and radish seed extract.
(b) 90 - 95℃에서 6 - 24시간동안 물로 열탕 추출하여 추출물을 얻는 단계; 및
(c)여과 및 건조하는 단계;를 포함하는 당뇨 예방 및 개선용 식품 조성물의 제조 방법.
(a) step of mixing in a weight mixing ratio of 1.716 heartburn, 1.225 mulberry fruit 1.225, omija fruit 1.225, sanjo seed 1.225, white ginseng 0.735, dansam root 0.735, namgasae fruit 0.735 and radish seed 0.735;
(b) obtaining an extract by hot water extraction with water at 90 - 95 °C for 6 - 24 hours; and
(C) filtration and drying step; diabetes prevention and method for producing a food composition for improvement comprising a.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210009573A KR102275824B1 (en) | 2021-01-22 | 2021-01-22 | The anti-diabetes composition containing extract mixture and manufaturing method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210009573A KR102275824B1 (en) | 2021-01-22 | 2021-01-22 | The anti-diabetes composition containing extract mixture and manufaturing method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102275824B1 true KR102275824B1 (en) | 2021-07-09 |
Family
ID=76865125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210009573A KR102275824B1 (en) | 2021-01-22 | 2021-01-22 | The anti-diabetes composition containing extract mixture and manufaturing method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102275824B1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050090867A (en) * | 2004-03-10 | 2005-09-14 | 한국 한의학 연구원 | Composition comprising schizandrae fructus extract for treatment of diabetes |
KR101908772B1 (en) | 2016-03-17 | 2018-10-16 | 대구가톨릭대학교산학협력단 | Anti-diabetic composition of mulberry twig hot water extract and oxyresveratrol as an efficient component and preparation method of the same |
-
2021
- 2021-01-22 KR KR1020210009573A patent/KR102275824B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050090867A (en) * | 2004-03-10 | 2005-09-14 | 한국 한의학 연구원 | Composition comprising schizandrae fructus extract for treatment of diabetes |
KR101908772B1 (en) | 2016-03-17 | 2018-10-16 | 대구가톨릭대학교산학협력단 | Anti-diabetic composition of mulberry twig hot water extract and oxyresveratrol as an efficient component and preparation method of the same |
Non-Patent Citations (2)
Title |
---|
Choi et al., Alleviating Effects of Mulberry Fruit Extract on Postprandial Hyperglycemia in Streptozotocin-induced Diabetic Mice. Journal of Life Science. 2016, Vol. 26. No. 8. pp. 921~927 1부.* * |
Niamat et al., A Review on Zizyphus as Antidiabetic. Journal of Applied Pharmaceutical Science. 2012, Vol. 02, No. 03, pp. 177-179 1부.* * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6345243B2 (en) | Enbu fermented food or beverage composition | |
KR102366919B1 (en) | Functional health food composition for inhibiting muscle reduction comprising a mixed extract of mulberry twig, Eucommia bark, Acanthopanax, and black bean | |
KR101565964B1 (en) | Composition Comprising Water Extracts from Pleurotus eryngii var. ferulea (Pf.). for Treating or Preventing hyperlipidemia | |
KR20160144791A (en) | Composition for relieving menopausal symptom | |
KR101578070B1 (en) | Health supplementing food for enhancing hair restoration, alleviating and improving hair loss, adjusting blood sugar, alleviating and improving gastrointestinal disorders | |
KR100771525B1 (en) | Composition for removing hangover comprising herbal mixture extract | |
KR102414431B1 (en) | A composition for improving, preventing and treating of diabetes mellitus | |
KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
KR102275824B1 (en) | The anti-diabetes composition containing extract mixture and manufaturing method thereof | |
KR101210748B1 (en) | Composition comprising the extract of Acanthopanax sessiliflorus and green tea for treating or alleviating hangover syndrome | |
KR20070097868A (en) | Composition comprising an allium cepa l. skin extract for preventing and treating diabetes mellitus | |
KR20150031373A (en) | Phamaceutical and food composition for preventing or treating obesity comprising extract of leaf from Hoppophea rhamnoids as effective component | |
KR101994483B1 (en) | Pharmaceutical composition comprising the sprout extracts of zingiber officinale as an effective component for prevention or treatment of diabetes and health functional food comprising the same | |
KR20180033781A (en) | Method of producing a food for preventing and improving diabetes | |
KR100827350B1 (en) | Herbal medicine composition for descending blood sugar | |
CN110800893A (en) | Sucrose-free beverage with effects of reducing blood fat, reducing weight, promoting digestion, clearing heat, tonifying spleen, promoting diuresis and reducing blood sugar and preparation method thereof | |
KR102302047B1 (en) | Composition for hepatoprotective and ameliorating hangover | |
KR100551464B1 (en) | Composition comprising an extract of Saururus chinensis BAILL. for preventing and treating diabetes mellitus | |
KR102478971B1 (en) | Composition for bowel movement promotion or diet | |
KR20200014567A (en) | A composition for improving, preventing and treating of liver diseases comprising Milk thistle | |
KR102203094B1 (en) | Composition for preventing and improving menstrual pain and skin troubles | |
KR20130029283A (en) | Composition for constipation | |
KR101976710B1 (en) | Composition for prevention, improvement or treatment of diabetes with extracts from Gynura procumbens leaf, Cornus officinalis and Pyrus ussuriensis | |
KR102216211B1 (en) | Pharmaceutical composition comprising the extract of an unripe apple as an effective component for prevention or treatment of diabetes and health functional food comprising the same | |
KR102185006B1 (en) | A composition for improving, preventing and treating of asthma and vascular disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |